

1 2 1 1 1 1* 2* 1.
100730 2.

100191

haemocoagulase agkistrodon HCA

he iv f ff 0 o



2020YFC2008305

*

Tel 010 85133620

Tel 010 82805019

2 ~ 3 RCTs
2 ~ 3
Meta 16 RCTs
2 Meta
RCTs 22-27 31 33 35 37-39 41-42
HCA
P < 0.01
1 RCT⁴⁰
HCA
P > 0.05
2 Meta
14
RCTs
Meta 16-17 12 RCTs 23-25 29 32-33 35 38-39 41-43
HCA
P < 0.01
2 RCT^{34 40}
HCA
P > 0.05
2 Meta

4 RCTs
16-17
14
2 RCTs³⁰
HCA
P > 0.05
HCA
P < 0.05
HCA

3 RCTs
Meta
16-17
1
RCT³⁷
HCA
P < 0.05
HCA
P < 0.05
HCA

2
HCA
P < 0.05
HCA
P < 0.05
HCA

2
Meta

4 HTA
g 3 5 A /Meta分析(n=2)
g 4 # . 0 n=4
g L ' . 0 n=22

4 F A ,) n=28
g HTA n=0
g 3 5 A /Meta分析(n=2)
g 4 # . 0 n=4
g L ' . 0 n=22

L n=37
g -) n=28
g 5 F n=4
g 9 * . 0 n=5

F E 3 9 -) n=176
PubMed n=34 The Cochrane Library n=21 Embase n=12
CBM n=12 CNKI n=46 Wanfang n=51

G 9) n=91

L B N ? 1 n=65

/ Meta

US

Shi ¹⁶	2015	RCT	14	1 382	HCA	<i>vs</i>
Xu ¹⁷	2015	RCT	12	1 031	HCA	<i>vs</i>

[illegible]

		/		/							
Chen ²²	2022	45.4 ± 5.5	45.9 ± 5.3	50 28/22	50 27/23	HCA 2 U		iv	0.9% NS 2 mL	iv	①②③④⑤⑥⑦⑧
Han ²³	2015	18 ~ 80	18 ~ 80	30 NA/NA	30 NA/NA	HCA 2 U		iv	0.9% NS 2 mL	iv	①②③④⑦⑧⑨⑩⑪⑫⑬
Liang ²⁴	2017	45.9 ± 29.1	51.2 ± 22.7	30 10/20	30 11/19	HCA 2 U		iv	0.9% NS 2 mL	iv	①②③④⑤⑥⑦⑧⑨⑩⑪⑫⑬⑭
Lü ²⁵	2014	18 ~ 80	18 ~ 80	30 NA/NA	30 NA/NA	HCA 2 U		iv	0.9% NS 2 mL		①②③④⑦⑧⑨⑩⑪⑫⑬
Xia ²⁶	2015	24 ~ 67	24 ~ 67	25 19/6	25 20/5	HCA 2 U		iv	0.9% NS 2 mL	iv	①②③④⑤⑥⑦⑧⑩⑪⑫⑬⑭⑮
Xia ²⁷	2017	24 ~ 67	24 ~ 67	25 17/8	25 19/6	HCA 2 U		iv	0.9% NS 2 mL	iv	①②③④⑤⑥⑦⑧⑩⑪⑫⑬⑭⑮
Yi ²⁸	2018	36 ~ 65	38 ~ 63	35 26/9	35 25/10	HCA 1 U		iv			①③④⑦⑮
Zhang ²⁹	2018	52.33 ± 9.76	51.8 ± 9.07	30 6/24	30 7/23	HCA 2 U			0.9% NS 2 mL		①③④⑨⑯
Wei ³⁰	2010	54.6 ± 13.4	56.2 ± 12.8	324 189/135	108 56/52	HCA 2 U		iv		2 U	①③④⑩⑪⑫⑬⑯
Chen ³¹	2019	/ 32.17 ± 3.33	32.15 ± 3.26	54 0/54	54 0/54	HCA 2 U		iv		2 mL	①③⑧⑩⑫⑬
Chen ³²	2016	56.73 ± 12.75	56.10 ± 16.63	30 19/11	30 12/18	HCA 2 U		4 h 1			①②③④⑤⑥⑨⑩⑫⑬⑯
Luo ³³	2015	≥ 18	≥			2 3 d iv					

RCTs	APTT	1	Meta	17
15	RCTs ^{22-29 31-33 35 37 42-43}	HCA		
	APTT			
	APTT			
	$P > 0.05$			4
RCTs ^{30 34 36 40}	HCA			
	APTT			
APTT			$P > 0.05$	
	④	fibrinogen	FIB	
1	Meta	18	RCTs	FIB
	1	Meta	17	14
RCTs ^{22-29 32-33 35 37 42-43}	HCA			
	FIB			
FIB			$P > 0.05$	
	4	RCTs ^{30 34 36 40}	HCA	
		FIB		
	FIB			
	$P > 0.05$			

HCA

ADR

- 13 HUSEREAU D DRUMMOND M PETROU S *et al.* Consolidated health economic evaluation reporting standards CHEERS statement J . *J Med Econ* 2013 16 6 713-719.
- 14 CUMPSTON M LI T PAGE M J *et al.* Updated guidance for trusted systematic reviews a new edition of the cochrane handbook for systematic reviews of interventions J . *Cochrane Database Syst Rev* 2019 10 ED000142.
- 15 HAILEY D. Toward transparency in health technology assessment a checklist for HTA reports J . *Int J Technol Assess Health Care* 2003 19 1 1-7.
- 16 SHI H K LI X L LIN X F *et al.* Effects of hemocoagulase agkistrodon for hemostasis in surgical tress vulnus a Meta-analysis J . *Chin J Pharmacoepidemiol* 2015 24 5 274-278.
- XU J Y ZHU M W JIANG H *et al.* Efficacy and safety of hemocoagulase Agkistrodon injection for intraoperative hemostasis a systematic review and Meta-analysis J . *Chin J Gen Surg*

- 1 FOWLER A J AHMAD T PHULL M K *et al.* Meta-analysis of the association between preoperative anaemia and mortality after surgery J . *Br J Surg* 2015 102 11 1314-1324.
- 2 VLAAR A P J JUFFERMANS N P. Transfusion-related acute lung injury a clinical review J . *Lancet* 2013 382 9896 984-994.
- 3 BOSBOOM J J KLANDERMAN R B ZIJP M *et al.* Incidence risk factors and outcome of transfusion-associated circulatory overload in a mixed intensive care unit population a nested case-control study J . *Transfusion* 2018 58 2 498-506.
- 4 KLEIN A A BAILEY C R CHARLTON A J *et al.* Association of Anaesthetists guidelines cell salvage for peri-operative conservation 2018 J . *Anaesthesia* 2018 73 9 1000-1005.
- 5 LIU Y C DU T K ZHU H D *et al.* Expert consensus on emergency management of non-traumatic hemorrhage *Chin J Emerg Med* 2019 19 10 850-856.
- 6 SHI G PANG J X KONG H Y *et al.* Evaluation of hemostatic effects of haemocoagulase Agkistrodon and the mechanisms J . *Chin J New Drug* 2013 22 11 1315-1319
- 7 QI Z GUO D H YAO C *et al.* The analysis of 399 ADRs related with hemocoagulase and the risk signals mining *Appl Monit* 2019 19 10 1000-1005
- 8 YAO C GUO D H WANG C Y *et al.* Factors related to Agkistrodon factors of allergic reaction related by haemocoagulase Agkistrodon for injection among 32203 patients by meta-analysis J . *Chin J Clin Pharmacol* 2019 36 3 346-350.
- 9 LI Y P YU J J SUN X. Exploring the process of rapid review J . *Chin J Evid-Based Med* 2014 14 5 497-500.
- 10 ZHENG Z H JIN B F ZHANG Y T. The effect of hemocoagulase Agkistrodon on assessment and the treatment of hemorrhage *Hainan Med J* 2019 20 10 1000-1005
- 11 TANG H L MEN P ZHAI S D. The effect of hemocoagulase Agkistrodon on the method of rapid review on drugs J . *Chin J Evid-Based Med* 2016 14 2 1-4.
- 12 GE L PAN B PAN J X *et al.* The effect of hemocoagulase Agkistrodon on the AMSTAR-2 A Quality Assessment Instrument for Systematic Reviews Including Randomized or Non-randomized Studies J . *Chin J Drug Eval* 2019 44 3 330-338.

7234 TD

62803

05j 00 7 275002

04 5002

569.

- 30 WEI J M ZHU M W ZHANG Z T *et al.* A multicenter phase
III trial of hemocoagulase Agkistrodon hemostasis coagulation
and safety in patients undergoing abdominal surgery J . *Chin*
Med J Engl 2010 123 5 589-593.

31